Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that MSI-H status confers therapeutic sensitivity to Dostarlimab in patients with Endometrial Carcinoma.

The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.

This statement is based on a regulatory approval from the European Medicines Agency:

JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.

Citation

GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2021-04-21	European Medicines Agency	Indication received approval from the European Commission.